PPARA and metabolic dysfunction-associated steatotic liver disease: Drugs targeting nuclear receptors for the treatment of NAFLD including pan-PPAR agonist (Lanifibranor), PPAR-α/δ agonists (elafibranor), PPAR-α/γ agonist (Saroglitazar) and FXR agonist (Obecholic acid) have been well summarised (48).